Clinical trial
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients…
NCT00215995 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00215995 |
|---|---|
| Title | Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas |
| Official title | A Phase II Study of Cisplatin and Irinotecan Induction Chemotherapy, Followed by ZD 1839 (IRESSA) in Adult Patients With Surgically Unresectable and/or Metastatic Esophageal or Gastric Carcinomas |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer |
| Intervention type | Drug |
| Interventions | Cisplatin, Irinotecan, ZD 1839 |
| Enrollment | 21 |
| Start date | Jul 1, 2003 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Jan 13, 2012 |
| Countries | Puerto Rico, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: